The mut-T homolog-1 (MTH1) inhibitor TH588 has shown promise in preclinical cancer studies but its targeting specificity has been questioned. Alternative mechanisms for the anti-cancer effects of TH588 have been suggested but the question remains unresolved. Here, we performed an unbiased CRISPR screen on human lung cancer cells to identify potential mechanisms behind the cytotoxic effect of TH588. The screen identified pathways and complexes involved in mitotic spindle regulation. Using immunofluorescence and live cell imaging, we showed that TH588 rapidly reduced microtubule plus-end mobility, disrupted mitotic spindles, and prolonged mitosis in a concentration-dependent but MTH1independent manner. These effects activated a USP28-p53 pathway -the mitotic surveillance pathway -that blocked cell cycle reentry after prolonged mitosis; USP28 acted upstream of p53 to arrest TH588treated cells in the G1-phase of the cell cycle. We conclude that TH588 is a microtubule-modulating agent that activates the mitotic surveillance pathway and thus prevents cancer cells from re-entering the cell cycle.
Centrosome:AURKA:TPX2:HMMR Aurora A signaling role of ran in mitotic spindle regulation Importin-alpha/Importin-beta/NuMA/Tpx2 NuMA/Tpx2 pronucleus p-S15,S20-TP53 Tetramer: TH588 is a microtubule-modulating agent. Mitotic spindle assembly is a process involving centrosomes and microtubules. Centrosomes duplicate during the S phase of the cell cycle, migrate to opposite cell poles during the prophase of mitosis, and organize bipolar spindles during the metaphase. To assess whether TH588 interferes with any of these processes, we investigated centrosome numbers and spindle morphology of mitotic cells in unsynchronized cell cultures. TH588 had no effect on centrosome duplication ( Supplementary Fig. S2A ) but decreased the separation of duplicated centrosomes in a concentration-dependent manner ( Fig. 2A,B and Supplementary Fig. S2B ). As a result, cells failed to position their microtubule asters in opposite cell poles and exhibited concentration-dependent degrees of spindle defects and lagging chromosomes. More than 50% of the mitotic cells showed monopolar spindles and uncongressed chromosomes at 4 µM TH588 (Fig. 2B ). In contrast, the temporal and spatial localization of aurora kinase A, polo-like kinase 1, and kinesin family member 23 was not altered, suggesting that spindles remained physically intact ( Supplementary Fig. S2B ).
Live-imaging showed that TH588 trapped cells in metaphase and mitotic duration increased in a concentration-dependent manner (Fig. 2C ,D and Supplementary Movies 1-3). Prolonged metaphase was coincidental with lagging chromosomes, suggesting that TH588 activated the spindle checkpoint. The delay was temporary and most cells eventually segregated their chromosomes and exited mitosis. However, at high concentrations of TH588, the majority of cells were permanently arrested in metaphase, or exited mitosis without division (mitotic slippage) ( Fig. 2E ). Flow cytometry of 5-ethynyl-2-deoxyuridine (EdU)-labeled cells confirmed that TH588 treatment led to accumulation of cells at the G2/M phase of the cell cycle ( Fig. 2F ,G), in agreement with increased mitotic duration and metaphase arrest.
We next tested the possibility that TH588 targets microtubules or microtubule dynamics by generating cells expressing the microtubule plus-end labeling EB1-GFP reporter ( Fig. 2H ). Live imaging of single cells before and after drug administration showed that TH588 markedly decreased the mobility of EB1-GFP complexes, and that plus-end immobilization occurred within minutes of drug administration ( Fig. 2H and Supplementary Movies 4, 5) . Similar experiments with cells expressing a tubulin-GFP fusion protein showed that TH588 reduced microtubule dynamics without altering microtubule filament density (Supplementary Movie 6). We conclude that TH588, by decreasing microtubule dynamics, disrupts assembly of bipolar spindles and chromosome congression in mitotic cells, thus causing metaphase arrest and prolonged mitoses.
TH588 disrupts mitotic spindles independently of MTH1. The mechanism we propose for the cytotoxic effect of TH588 differs from the original proposal, namely inhibition of MTH1-mediated sanitation of the nucleotide pool 1 , but it remains possible that inhibition of MTH1 contributes to the drug effect. To address this, we designed two gRNAs targeting ubiquitous exons in MTH1 ( Supplementary Fig. S3A ) and produced MTH1-knockout batch clones ( Fig. 3A and Supplementary Fig. S4A ). Knockout of MTH1 did not affect growth or colony formation of H460 cells compared to isogenic controls ( Fig. 3B,C) . Thus, inactivation of MTH1 did not reproduce the drug effect. Moreover, TH588 reduced the growth and viability of MTH1-deficient cells to the same extent as control cells, showing that MTH1 is dispensable for the drug effect. MTH1 knockout did not affect centrosome separation, formation of bipolar spindles, or chromosome congression in mitotic cells, and MTH1 knockout did not abolish or attenuate the impact of TH588 on the same features ( Fig. 3D ,E). Thus, MTH1 inhibition does not contribute to TH588's effect on mitotic spindles. TH588 induces USP28-and p53-dependent G1 arrest. Three independent CRISPR screens previously identified a USP28-p53 pathway -the mitotic surveillance pathway 17 -that mediates cell cycle arrest after centrosome loss or prolonged mitosis [18] [19] [20] . Since TH588 caused prolonged mitoses and TP53 (the gene encoding p53) and USP28 was highest ranked in our screen (Fig. 1C ), we hypothesized that the TH588-effect on mitotic spindles activates the USP28-p53 pathway. To test this, we infected H460 cells with single lentiviral gRNAs targeting TP53 or USP28 and generated knockout batch clones (Fig. 4A,B and Supplementary Figs S3B,C and S4B,C). www.nature.com/scientificreports www.nature.com/scientificreports/ Cells infected with non-targeting gRNAs were used as negative controls. One gRNA (TP53 A) targeting exon-3 of TP53 failed to reduce the amount of p53, but instead generated a truncated p53 protein that migrated faster in gel electrophoresis ( Supplementary Fig. S5 ). The other gRNAs produced knockout batch clones with varying amounts of contaminating wildtype cells. www.nature.com/scientificreports www.nature.com/scientificreports/ We evaluated the batch clones for colony formation at increasing TH588 concentrations. USP28-knockout batch clones showed increased colony formation at all drug concentrations compared to controls (Fig. 4C) . Similar results were obtained for TP53: Three batch clones showed increased colony formation at all concentrations (Fig. 4C ), and one showed increased colony formation at the highest concentration (P < 0.01). These results indicate that USP28 and TP53 are part of the effector mechanism downstream of TH588.
The aforementioned CRISPR screens showed that USP28 and p53 prevent cells from re-entering the cell cycle after prolonged mitosis by arresting cells at the G1 phase of the next cell cycle [18] [19] [20] . To investigate whether TH588 eliminates cancer cells by a similar mechanism, cells were treated with TH588 for 24 hours to ensure that they were exposed to the drug during at least one mitosis, and with TH588 plus EdU for another 24 hours to determine whether the cells enter a second cell cycle (Fig. 4D ). TH588 increased the percentage of EdU-negative cells in the G1 phase of the cell cycle, and thus prevented cells from re-entering the cell cycle (Fig. 4E,F) . In contrast, more than 98% of the untreated cells were EdU-positive and thus re-entered a second cell cycle. The long exposure to TH588 also induced apoptosis, as evidenced by an expanded sub-G1 population (Fig. 4E,F) .
To assess whether p53 and USP28 were involved in the growth arrest, we repeated the experiment with TP53-and USP28-knockout batch clones. TP53 deficiency markedly reduced the accumulation of EdU-negative cells in the G1 phase of the cell cycle compared to controls, and increased the proportion of EdU-positive cells (Fig. 4G,H) . Similar results were obtained with USP28-knockout batch clones, but the effect was weaker (Fig. 4G,I) . The weaker effect was likely caused by contamination of wildtype cells that will mask a dependency on USP28. We conclude that p53 and USP28 prevent TH588-treated cells from re-entering the cell cycle after exiting prolonged mitoses. Of note, TH588-treated batch clones (knockouts and controls) showed fewer apoptotic cells compared to naive H460 cells, possibly as a result of the insertion of lentivirus into the genome.
Since USP28 is a ubiquitin-specific peptidase that activates p53 by removing ubiquitin in response to centrosome loss or prolonged mitosis 18 , we hypothesized that TH588 activates p53 in a USP28-dependent manner. As expected, TH588 concentration-dependently increased p53 levels with an effect size similar to the DNA-damaging drug etoposide ( Fig. 4J and Supplementary Fig. S4D ). To address whether USP28 is required for p53 activation, we generated homozygous USP28-knockout clones from single cells to circumvent the influence of wildtype or heterozygous cells in the batch clones. Strikingly, there was no difference in p53 levels between untreated and TH588-treated USP28 −/− cells (Fig. 4K,L and Supplementary Fig. S4E ). We therefore conclude that USP28 is required for p53 activation by TH588.
Discussion
We performed an unbiased CRISPR screen to identify knockouts that rescue growth of TH588-treated lung cancer cells. The screen identified a densely connected network of pathways and complexes involved in mitotic spindle regulation, suggesting that TH588 directly or indirectly targets mitotic spindles. In support of this, we show that TH588 concentration-dependently: (1) decreased centrosome separation in mitotic cells, (2) increased the occurrence of monopolar spindles and lagging chromosomes, (3) increased mitotic duration and mitotic slippage, and (4) markedly decreased microtubule dynamics. Importantly, TH588 affected mitotic spindles and microtubule dynamics at the same concentrations that decreased growth and viability of cancer cells in this and other studies 1,3-7 .
While it may seem counterintuitive that inactivation of important regulators of spindle formation promoted growth of TH588-treated cells, positive selection in drug-gene interaction screens could have many underpinnings. Spindle formation is driven by redundant pathways and perturbation of one pathway can be compensated for by the upregulation of others 21, 22 . Hence, inactivation of spindle regulators may precondition cells to tolerate TH588 better compared to other cells in the mutant cell pool.
Although we have shown that TH588 is a microtubule-modulating agent, we have not identified its direct target(s). TH588 reduced microtubule dynamics within minutes of drug administration, excluding mechanisms that require transcription, translation, or accumulation of slow-forming metabolites. Moreover, TH588 reduced microtubule dynamics during the interphase of the cell cycle, thus arguing against targets that are confined to the mitotic apparatus, and without disrupting microtubule filaments, suggesting that it may belong to the "kinder and gentler" category of microtubule-modulating agents including noscapinoids 23 . These gentler agents are expected to have less adverse effects than other tubulin-targeting agents.
The mode of action we propose for the cytotoxic effect of TH588 differs from that proposed originally, namely that TH588, by targeting MTH1 and the degradation of oxidized nucleotides, induced replication stress and DNA damage signaling via ataxia telangiectasia mutated (ATM) 1 . Of note, gRNAs targeting ATM were not enriched in our screen, and knockout of MTH1 neither recapitulated nor attenuated the effect of TH588 on cell growth or mitotic spindle assembly. We conclude therefore that targeting MTH1 is not sufficient or required to reduce microtubule dynamics; however, we cannot exclude the possibility that MTH1 inhibition and accumulation clones and non-targeting controls after 48-hour incubation with TH588 (6 µM) and 24-hour incubation with EdU. Cell populations were defined as in (E). Graphs showing cell cycle distribution (n = 4 batch clones/ gRNA). (J) Western blots of protein extracts from cells incubated with DMSO or TH588 for 24 hours, with antibodies against p53. Protein extracts from etoposide (Eto)-treated cells (5 µM) were used as positive control. Actin was used as loading control. (K,L) Western blots of protein extracts from USP28 −/− and USP28 +/+ clones treated with DMSO or TH588 for 24 hours, with antibodies against p53 and USP28. Actin was used as loading control. Graph showing levels of p53 normalized against actin (n = 3). Statistics used were one-way ANOVA (A,B,L), two-way ANOVA (C), and two-way ANOVA, simple effects within rows (H,I). *q < 0.05, **q < 0.01, ***q < 0.001, ****q < 0.0001. Graphs show mean +/− SEM.
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(2019) 9:14667 | https://doi.org/10.1038/s41598-019-51205-w www.nature.com/scientificreports www.nature.com/scientificreports/ of oxidized nucleotides contribute to TH588's anticancer effect in vivo. Indeed, the anticancer effects of other microtubule-modulating agents including vinca alkaloids and taxanes are potentiated by oxidative stress 24, 25 .
Our results are consistent with those of an earlier study that investigated alternative mechanisms of TH588 and showed that: (1) TH588-treated cells had a proteomic profile that resembled those generated by tubulin-modulating drugs, (2) TH588 arrested cells in the G2/M phase of the cell cycle, and (3) TH588 inhibited tubulin polymerization in a cell-free system 6 . The latter finding is important because it suggests that TH588 interacts directly with tubulin polymers. Decreased tubulin polymerization required substantially higher concentrations of TH588 (10-30 µM) 6 than those affecting centrosome separation, spindle assembly, chromosome congression, and mitotic duration in our study (1-2 µM). However, compounds that decrease microtubule polymerization at high concentrations are known to suppress microtubule dynamics at 10-100 fold lower concentrations 26 . Hence, TH588 may interact directly with tubulin polymers.
We also identified a novel effector mechanism that prevents TH588-treated cells from re-entering the cell cycle after prolonged mitosis by arresting cells at the G1 phase of the cell cycle. This mechanism is dependent on USP28 activation of p53 and is supported by our observations showing that: (1) knockout of USP28 or TP53 rescued colony formation of TH588-treated cells, (2) long-term TH588 treatment arrested cells at the G1 phase of the cell cycle in a USP28-and TP53-dependent manner, and (3) knockout of USP28 abolished p53 activation by TH588.
The effector mechanism is probably identical to the recently identified P53BP1-USP28-TP53-CDKN 1A-dependent mitotic surveillance pathway that induces G1-arrest after centrosome loss or prolonged mitosis [17] [18] [19] , which suggests a role for p53 binding protein-1 (P53BP1) and cyclin-dependent kinase inhibitor-1A (CDKN1A, p21) in the TH588 effector mechanism. In support of this, we observed that TH588 concentration-dependently increased the amount of CDKN1A in H460 cells (data not shown), and gRNAs targeting CDKN1A ranked high in our screen (but did not reach significance). P53BP1 was not targeted in the screen, but previous data show that TH588 increases the number of P53BP1 foci in U2OS cells 1 . We therefore propose that the mechanism underlying the cytotoxic effect of TH588 involves P53BP1 and CDKN1A, but this possibility remains to be tested.
Our observation that TH588 arrested cells at the G1 phase contrasts with an earlier publication showing that TH588 arrested cells at the G2 phase of the cell cycle 6 . However, live imaging in our study revealed that TH588 prolonged mitosis by arresting cells at the metaphase, in agreement with the previously published data 6 , but also showed that the majority of the arrested cells eventually exited mitosis. A substantial proportion of these cells were arrested at the G1 phase of the cell cycle and thus were prevented from re-entering the cell cycle. Thus, the major growth-limiting mechanism of TH588 is p53-dependent G1 arrest. However, sustained exposure to TH588 and stalled mitosis may lead to other irremediable outcomes that do not require p53. In line with this, TH588 is toxic to several cancer cell lines with validated p53 mutations 1 .
One weakness of this study is the use of gRNA libraries that targeted cell cycle and kinase genes only. We might have identified additional mechanisms by using genome-wide libraries. However, the concentration-dependent effect on mitotic spindles, instant reduction of microtubule dynamics, and prompt rescue by USP28 or TP53 knockout suggest that we have identified the main mechanism of action responsible for the anticancer effect of TH588. Future studies are required to determine if there are additional mechanisms involved and to define the molecular target of TH588.
Microtubule-modulating agents have been the cornerstone of cancer treatment for more than 50 years 27 . However, the manufacture of these often natural or semi-synthetic compounds is laborious and expensive, and their use is restricted by adverse effects and resistance development. Novel synthetic microtubule-modulating agents, such as TH588, which is well tolerated in mice, are therefore highly requested and expected to complement existing chemotherapies. Controversies regarding the validity of MTH1 as a cancer drug target should not stand in the way of future clinical development of TH588 or its structural homologs.
In summary, we performed an unbiased CRISPR screen to identify pharmacological mechanisms of the MTH1-inhibitor TH588. We found that TH588 is a novel microtubule-modulating agent that attenuates mitotic spindle assembly and eliminates cancer cells by the mitotic surveillance pathway. The mechanism is distinct from the original concept in which TH588 caused replication stress by targeting MTH1 and the degradation of oxidized nucleotides. The result opens up for continued clinical development of TH588 that shows promising results in preclinical cancer studies.
Materials and Methods
Cell culture. H460 cells are derived from a large-cell carcinoma, harbor somatic mutations or copy number alterations in KRAS, PI3KCA, STK11, KEAP1, and CDKN2A, and show intermediate sensitivity towards TH588 (https://cancer.sanger.ac.uk/cell_lines). H460 cells were cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% inactivated fetal bovine serum (FBS), 2 mM glutamine, 5 mM non-essential amino acids, and penicillin/streptomycin (100 U/ml). HEK293T cells were cultured in DMEM supplemented with 4 mM glutamine and 10% FBS. The cells were obtained from the American Type Culture Collection (ATCC).
Generation of doxycycline-inducible FLAG-Cas9-expressing cells. Doxycycline-inducible
FLAG-Cas9-expressing cells (dox-FLAG-Cas9) were generated from H460 cells infected with lentivirus carrying the pCW-Cas9 vector (packaged by Cyagene) and cultured for 3 days in puromycin. Clones were generated from single cells and tested for FLAG-Cas9 expression by western blotting of protein extracts from cells incubated with 1 µg/ml doxycycline, with antibodies against FLAG. pCW-Cas9 was a kind gift from David Sabatini & Eric Lander (Addgene # 50661) 28 .
Production of lentiviral human CRISPR knockout pooled gRNA libraries. The human CRISPR enriched pooled library was a gift from David Sabatini & Eric Lander (Addgene # 51044, 51046, and 51048) 16 . Sub-pools of plasmid libraries enriched for cell cycle and kinase targets were prepared as described 28 www.nature.com/scientificreports www.nature.com/scientificreports/ libraries were amplified by transformation in XL-10 gold chemical competent Escherichia coli (Stratagene) and harvested using endotoxin-free plasmid maxiprep kit (Qiagen) according to the manufacturer's protocol. For virus production, HEK293T cells were co-transfected with plasmid libraries and pCMV-dR8.2 (Addgene # 8455) and pCMV-VSV-G vectors (Addgene # 8454) using the Xtreme gene 9 transfection reagent (Roche). Virus-containing culture media was harvested 60 hours after transfection, centrifuged at 4700 g for 15 minutes at 4 °C, passed through 0.45 µm filters to remove cell debris, and stored in aliquots at −80 °C. The virus titers were determined as in 28 .
Pooled lentiviral screen. Dox-FLAG-Cas9 cells were transduced with lentivirus libraries at a titer producing 50% infected cells, and cultured with blasticidine (5 µg/ml) and doxycycline (1 µg/ml) for 7 days to generate complex mutant cell pools for screening. 15-30 million cells were infected in order to maintain 200-fold coverage with respect to the number of gRNAs in the libraries (10,257 gRNAs targeting 1000 cell cycle genes and 5070 gRNAs targeting 500 kinases). The mutant cell pools were passaged every third day in medium containing: (1) 4 µM TH588, (2) 2 µM auranofin, (3) DMSO, or (4) without drugs or DMSO until the untreated control cells had divided 14 times. The 200-fold coverage was maintained at all stages of the screen.
Preparation of sequencing libraries. Lentiviral inserts were PCR amplified from genomic DNA using a nested PCR protocol with outer primers targeting the virus backbone 16 and custom inner primers with binding sequences for Illumina Nextera adaptor read1 and read2 attached to the 5′-ends. After product purification using a PCR cleanup kit (Macherey and Nagel), a third PCR using Illumina Nextera indexing primers (N7xx and S5xx) produced the final sequencing libraries that were diluted, pooled, and sequenced on a HiSeq2500 (Illumina) with paired-end 125 bp read length, and v4 sequencing chemistry. The sequencing was done at the SciLife core facility at Uppsala University. The primers are listed in Supplementary Table 1 .
Sequencing data preprocessing and quality control. Sequencing reads were mapped to gRNA sequences and principal component analysis was carried out with MAGeCK-VISPR 29 version 0.5.3, specifying the parameters "-reverse-complement", "-sgrna-len 20" and "-trim 73", otherwise using default settings. Read count histograms were produced with R.
Statistical tests for gene selection.
To find genes that may be subject to either positive or negative selection under TH588 or auranofin treatment, tests for gRNA enrichment or depletion were performed with the maximum likelihood estimation (MLE) algorithm implemented in MAGeCK-VISPR 29 0.5.3. This method allows the simultaneous estimation of gene selection for multiple treatments, while also weighing the effect of each gRNA by its estimated efficiency. Parameters used for the MLE algorithm were: "update-efficiency: true", "trim-5: 73", "len: 20" and "-permutation-round 1000", otherwise default settings. Untreated and DMSO-treated samples were both specified as controls in the design matrix. Enrichment analyses. To investigate common biological themes among the top ranking genes, overrepresentation analyses were carried out using ConsensusPathDB 30 . For this analysis, ranked gene lists of the cell cycle and kinase libraries were combined, and a combined background of all cell cycle and kinase library genes was used as a reference. Tests were performed for the Gene Ontology 31 collections "cellular component", "molecular function" and "biological process", as well as pathways and protein complexes derived from Reactome 32 , BioCarta, CORUM 33 and PID 34 . To further investigate putative interactions between proteins encoded by candidate genes, the online STRING database tool 35 was used.
Immunofluorescence. Cells were plated onto glass cover slips in 24-well plates then fixed with formalin or methanol and permeabilized with Triton-X100 in PBS. Cover slips were blocked with fetal bovine serum in PBS or bovine serum albumin in PBST (0.1% Tween-20 in PBS) before incubating with primary and secondary antibodies in PBS. Cover slips were mounted onto microscope slides with Fluoroshield Mounting Medium containing DAPI (ab104139, Abcam). Primary antibodies used were anti-α-tubulin (1:2000, T3559, Sigma-Aldrich), anti-pericentrin (1:1500, ab4448, Abcam), anti-aurora kinase A (1:3000, ab13824, Abcam), anti-polo-like kinase 1 (1:100, sc-17783, Santa Cruz), and anti-kinesin family member 23 (1:500, HPA045208, Atlas antibodies). Secondary antibodies used were anti-mouse-488 (1:250, ab150117, abcam), anti-rabbit-594 (1:250, ab150080, abcam), and anti-rabbit-Cy3 (1:250, ab6939, abcam). Fluorescent images were acquired with an Axioplan 2 microscope (Carl Zeiss) and an AxioCam MRm Camera (Carl Zeiss), or an LSM 880 Airyscan microscope (Carl Zeiss). Live imaging of DNA stained cells. Unsynchronized cells were plated at low confluence onto glass bottom cell imaging 24-well plates (Eppendorf) in DMEM lacking indicator dye 24 hours before the experiment started, with addition of SirDNA Hoeshst (1 µM final concentration, Tebu-bio) 16 hours before start, and TH588 (2-8 µM final concentration) or DMSO 2 hours before start. Time lapse image series were generated using a cell^R microscope and scan^R screening station (Olympus), with 10 minute increments between images. Calculations of mitotic duration was done with MatLab, and percentage of metaphase arrested cells with ImageJ.
